Ends

GGTOOR, Inc., (OTCMKTS:GTOR) Announces Management Report for the Week Ended August 6, 2022

Retrieved on: 
Tuesday, August 9, 2022

The newest addition to the Yu-Gi-Oh! Duel Links meta -- the anti-synchro deck, Meklords -- dominated this weekend at GGtoor x DLE Yu-Gi-Oh! Duel Links Showdown #32! Many players brought Meklords to counter the synchro-based, Rose Dragon deck that won Showdown #31 two weeks ago. While some of the decks from the previous meta, such as D/D/D, were able to keep up with Rose Dragons in the last Showdown, it seems that they could not deal with both Rose Dragons AND Meklords this time around. These 2 decks absolutely tore up the competition, with the two archetypes EACH representing about 1/3 of the Top 32 cut, and a combined six of the Top eight slots! However, These 2 decks that would reach the finals were neither Rose Dragons nor Meklords; the first was EndS' Galaxy-Eyes, a deck famous for often getting 2nd place in prior metas. The other was Teiko's Phantom Knights, the meta king from the beginning of the year.

Key Points: 
  • Many players brought Meklords to counter the synchro-based, Rose Dragon deck that won Showdown #31 two weeks ago.
  • The other was Teiko's Phantom Knights, the meta king from the beginning of the year.
  • However, EndS' Galaxy-Eyes, with its early-game aggression, out-muscled Phantom Knights Game 2, but not before Teiko revealed EndS' "Shadow-Imprisoning Mirror" tech.
  • Game 3 then progressed similar to Game one, but EndS was prepared for a long-game with his "Shadow-Imprisoning Mirror."

Chemical Insights Research Institute Receives Prestigious Award from the National Institutes of Health

Retrieved on: 
Thursday, May 5, 2022

Chemical Insights Research Institute (CIRI) of Underwriters Laboratories , in partnership with Purdue University and Georgia State University, has been awarded a National Institutes of Health (NIH) grant to establish the risk factors and biomarkers of gingival inflammation, the precursor to periodontal disease, associated with ENDS usage.

Key Points: 
  • Chemical Insights Research Institute (CIRI) of Underwriters Laboratories , in partnership with Purdue University and Georgia State University, has been awarded a National Institutes of Health (NIH) grant to establish the risk factors and biomarkers of gingival inflammation, the precursor to periodontal disease, associated with ENDS usage.
  • These hazardous chemical mixtures may cause disease risks, but there is a lack of data linking ENDS preference, usage behavior, and oral health outcomes.
  • That is why we are eager to share this research and provide actionable data to help increase positive health outcomes.
  • The research institutes of Underwriters Laboratories Inc. are nonprofit organizations dedicated to advancing the Underwriters Laboratories public safety mission through scientific discovery.

GGTOOR, Inc., (OTCMKTS:GTOR) Announces Management Report for the Week Ended April 30, 2022

Retrieved on: 
Tuesday, May 3, 2022

THOMASVILLE, GA, May 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GGTOOR, Inc., (OTCMKTS:GTOR) (“GGTOOR, Inc.,”, “GTOR”, or the “Company”), an emerging leader in the eSports markets, announces progress continues on the deal that was announced last week. One of the most critical and devastating consequences of penny stock issuers making a big move or striking a big transaction is massive dilution. John V Whitman Jr., GGToor Inc., CEO had this to say, “I am very excited to inform shareholders and interested persons, if and when our deal is inked and based on the current proposed structure, the dilution to shareholders will be a mere 15,000,000 shares of “Restricted Common Stock” or a modest .071% of the current total issued and outstanding of 209,119,362. This means, when executed, the Company will improve its balance sheet in excess of $100,000,000 in exchange for less than $300,000 worth of Common Stock at the closing stock price of $0.02 yesterday, May 2, 2022. I will also proudly announce that no future dilution will occur as a result of this proposed transaction. This is a transaction that will have every CEO in the United States asking themselves, how in the world did GGToor pull this off.”

Key Points: 
  • I will also proudly announce that no future dilution will occur as a result of this proposed transaction.
  • The Company will continue to share additional details each week until the deal closes.
  • However, EndS had a more fortunate run, making it all the way to the finals, facing off against Soliman_ali.
  • In addition, the company plans to operate a few subsidiary companies from high tech data management businesses to product and support businesses.